{
    "clinical_study": {
        "@rank": "95765", 
        "arm_group": {
            "arm_group_label": "BIW-8962", 
            "arm_group_type": "Experimental", 
            "description": "Phase 1 - Dose escalation based on the BIW-8962 tolerability and safety data obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur\nPhase 2 - Recommended dose determined in Phase 1"
        }, 
        "brief_summary": {
            "textblock": "This Phase 1/2 study is designed to assess the following: safety and tolerability of\n      BIW-8962, Dose Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), Recommended Phase 2\n      Dose (RP2D) in Phase 1 in subjects with advanced/recurrent lung cancers or mesothelioma and\n      preliminary efficacy in Phase 2 in subjects with advanced/recurrent Small Cell Lung Cancer."
        }, 
        "brief_title": "Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC), Mesothelioma", 
            "Phase 2 Portion : Small Cell Lung Cancer(SCLC)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Mesothelioma", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Phase 1: histopathological-documented, measurable or non-measurable unresectable,\n             advanced primary or recurrent SCLC, NSCLC or mesothelioma\n\n          -  Phase 2: measurable, unresectable advanced or recurrent SCLC\n\n          -  A life expectancy > 3 months\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 at study\n             entry\n\n          -  Echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection\n             fraction (LVEF) \u2265 50%, or \u2265  institution's established lower limit of normal\n\n          -  Adequate hematologic, hepatic, renal and lung function\n\n        Exclusion Criteria:\n\n          -  Subject received cytotoxic anti-cancer chemotherapy, orally available signaling\n             pathway-targeted therapy, hormonal therapy, radiotherapy, immunotherapy, or\n             investigational agents within 3 weeks prior to the first dose\n\n          -  Subject received monoclonal antibodies within 4 weeks of the first dose\n\n          -  Major surgery within 4 weeks prior to the first dose\n\n          -  Known symptomatic brain metastases\n\n          -  Clinically significant cardiovascular disease\n\n          -  Leptomeningeal disease\n\n          -  Uncontrolled intercurrent illness including ongoing or active infection, uncontrolled\n             diabetes, etc\n\n          -  Known HIV disease or acquired immunodeficiency syndrome-related illness\n\n          -  A psychiatric illness, disability or social situation\n\n          -  Hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins\n\n          -  A history of primary brain/CNS malignancy\n\n          -  Neurological paraneoplastic syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898156", 
            "org_study_id": "8962-002"
        }, 
        "intervention": {
            "arm_group_label": "BIW-8962", 
            "description": "Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached.  BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.\nPhase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops.", 
            "intervention_name": "BIW-8962", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 28, 2014", 
        "location": {
            "contact": {
                "last_name": "KYOWA HAKKO KIRIN KOREA"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin Korea"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Advanced/Recurrent Lung Cancer or Mesothelioma", 
        "overall_contact": {
            "email": "clinical.info@kyowa-kirin.co.jp", 
            "last_name": "KYOWA HAKKO KIRIN KOREA"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Phase 1 -Adverse Event collection and assessment will be done for all potentially treated subjects to assess the safety, tolerability, and determine the DLTs, maximum tolerated dose (MTD).", 
                "measure": "Phase 1 -  To determine Maximum Tolerated Dose(MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "First 3-week cycle of treatment"
            }, 
            {
                "description": "Phase 2 - Tumor response and progression will be evaluated every 6 weeks using RECIST v 1.1. Partial Response (PR) or Complete Response (CR) will be confirmed 4 weeks after first detection of response.", 
                "measure": "Phase 2 -  To assess the objective response rate(Partial Response and Complete Response)", 
                "safety_issue": "Yes", 
                "time_frame": "Until Progressive Disease (PD) determined"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898156"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Phase 1 - Tumor response progression will be evaluated using RECIST V1.1 for the assessment of efficacy", 
                "measure": "Phase 1 - To evaluate preliminary efficacy", 
                "safety_issue": "No", 
                "time_frame": "Until Progressive Disease (PD) determined"
            }, 
            {
                "description": "Phase 1 - Pharmacokinetic (PK) parameters such as Maximum concentration (Cmax), time to maximum concentration (Tmax), minimum concentration(Cmin), area under the curve (AUC), half-life (t1/2), clearance (CL), and etc., are assessed.", 
                "measure": "Phase 1 - To determine the q3w pharmacokinetic profile of BIW-8962", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, and Day 1, 2, 3, 5, 8, 12 and 15 in Cycle 1 and 3, Pre-dose in Cycle 2, 4, 5,and up to Cycle 6"
            }, 
            {
                "description": "Phase 2 - All safety information will be collected and then evaluated.", 
                "measure": "Phase 2 - To assess safety and tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "Every 3 weeks, until 45days after the last dose or within 7 days prior to the initiation of subsequent anti-cancer treatment"
            }
        ], 
        "source": "Kyowa Hakko Kirin Korea Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Korea Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}